Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans

Barry A. Borlaug, Vojtech Melenovsky, Tricia Marhin, Patricia Fitzgerald, David A Kass

Research output: Contribution to journalArticle

Abstract

Background - Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGMP and to induce vasodilation. This effect has led to its use for treating erectile dysfunction. Although its influence on rest heart function has appeared minimal, recent animal studies suggest that sildenafil can have potent effects on hearts stimulated by β-adrenergic or pressure overloads. We therefore tested whether sildenafil blunts dobutamine-stimulated cardiac function in humans. Methods and Results - Thirty-five healthy volunteers underwent a randomized, double-blind, placebo-controlled study in which cardiac function was assessed in response to dobutamine before and after oral sildenafil (100 mg, n = 19) or placebo (n = 16). Echo Doppler and noninvasive blood pressure data yielded load-independent contractility indexes (maximal power index and end-systolic elastance), ejection fraction, and measures of diastolic function. In the initial dobutamine test, systolic and diastolic function improved similarly in both treatment groups (eg, peak power index rose 80±28% in the placebo group and 82±31% in the sildenafil group; P=NS). However, in subjects who then received sildenafil, their second dobutamine response was significantly blunted, with peak power, ejection fraction, and end-systolic elastance changes reduced by 32±34%, 66±64%, and 56±63%, respectively (each P

Original languageEnglish (US)
Pages (from-to)2642-2649
Number of pages8
JournalCirculation
Volume112
Issue number17
DOIs
StatePublished - Oct 25 2005

Fingerprint

Adrenergic Agents
Dobutamine
Placebos
Type 5 Cyclic Nucleotide Phosphodiesterases
Erectile Dysfunction
Vasodilation
Sildenafil Citrate
Healthy Volunteers
Blood Pressure
Pressure
Power (Psychology)

Keywords

  • Contractility
  • Pharmacology
  • Phosphodiesterase 5
  • Receptors, adrenergic, beta
  • Sildenafil

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans. / Borlaug, Barry A.; Melenovsky, Vojtech; Marhin, Tricia; Fitzgerald, Patricia; Kass, David A.

In: Circulation, Vol. 112, No. 17, 25.10.2005, p. 2642-2649.

Research output: Contribution to journalArticle

Borlaug, BA, Melenovsky, V, Marhin, T, Fitzgerald, P & Kass, DA 2005, 'Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans', Circulation, vol. 112, no. 17, pp. 2642-2649. https://doi.org/10.1161/CIRCULATIONAHA.105.540500
Borlaug, Barry A. ; Melenovsky, Vojtech ; Marhin, Tricia ; Fitzgerald, Patricia ; Kass, David A. / Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans. In: Circulation. 2005 ; Vol. 112, No. 17. pp. 2642-2649.
@article{ddcd332e6c5046bcb82282a7230dab0b,
title = "Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans",
abstract = "Background - Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGMP and to induce vasodilation. This effect has led to its use for treating erectile dysfunction. Although its influence on rest heart function has appeared minimal, recent animal studies suggest that sildenafil can have potent effects on hearts stimulated by β-adrenergic or pressure overloads. We therefore tested whether sildenafil blunts dobutamine-stimulated cardiac function in humans. Methods and Results - Thirty-five healthy volunteers underwent a randomized, double-blind, placebo-controlled study in which cardiac function was assessed in response to dobutamine before and after oral sildenafil (100 mg, n = 19) or placebo (n = 16). Echo Doppler and noninvasive blood pressure data yielded load-independent contractility indexes (maximal power index and end-systolic elastance), ejection fraction, and measures of diastolic function. In the initial dobutamine test, systolic and diastolic function improved similarly in both treatment groups (eg, peak power index rose 80±28{\%} in the placebo group and 82±31{\%} in the sildenafil group; P=NS). However, in subjects who then received sildenafil, their second dobutamine response was significantly blunted, with peak power, ejection fraction, and end-systolic elastance changes reduced by 32±34{\%}, 66±64{\%}, and 56±63{\%}, respectively (each P",
keywords = "Contractility, Pharmacology, Phosphodiesterase 5, Receptors, adrenergic, beta, Sildenafil",
author = "Borlaug, {Barry A.} and Vojtech Melenovsky and Tricia Marhin and Patricia Fitzgerald and Kass, {David A}",
year = "2005",
month = "10",
day = "25",
doi = "10.1161/CIRCULATIONAHA.105.540500",
language = "English (US)",
volume = "112",
pages = "2642--2649",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "17",

}

TY - JOUR

T1 - Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans

AU - Borlaug, Barry A.

AU - Melenovsky, Vojtech

AU - Marhin, Tricia

AU - Fitzgerald, Patricia

AU - Kass, David A

PY - 2005/10/25

Y1 - 2005/10/25

N2 - Background - Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGMP and to induce vasodilation. This effect has led to its use for treating erectile dysfunction. Although its influence on rest heart function has appeared minimal, recent animal studies suggest that sildenafil can have potent effects on hearts stimulated by β-adrenergic or pressure overloads. We therefore tested whether sildenafil blunts dobutamine-stimulated cardiac function in humans. Methods and Results - Thirty-five healthy volunteers underwent a randomized, double-blind, placebo-controlled study in which cardiac function was assessed in response to dobutamine before and after oral sildenafil (100 mg, n = 19) or placebo (n = 16). Echo Doppler and noninvasive blood pressure data yielded load-independent contractility indexes (maximal power index and end-systolic elastance), ejection fraction, and measures of diastolic function. In the initial dobutamine test, systolic and diastolic function improved similarly in both treatment groups (eg, peak power index rose 80±28% in the placebo group and 82±31% in the sildenafil group; P=NS). However, in subjects who then received sildenafil, their second dobutamine response was significantly blunted, with peak power, ejection fraction, and end-systolic elastance changes reduced by 32±34%, 66±64%, and 56±63%, respectively (each P

AB - Background - Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGMP and to induce vasodilation. This effect has led to its use for treating erectile dysfunction. Although its influence on rest heart function has appeared minimal, recent animal studies suggest that sildenafil can have potent effects on hearts stimulated by β-adrenergic or pressure overloads. We therefore tested whether sildenafil blunts dobutamine-stimulated cardiac function in humans. Methods and Results - Thirty-five healthy volunteers underwent a randomized, double-blind, placebo-controlled study in which cardiac function was assessed in response to dobutamine before and after oral sildenafil (100 mg, n = 19) or placebo (n = 16). Echo Doppler and noninvasive blood pressure data yielded load-independent contractility indexes (maximal power index and end-systolic elastance), ejection fraction, and measures of diastolic function. In the initial dobutamine test, systolic and diastolic function improved similarly in both treatment groups (eg, peak power index rose 80±28% in the placebo group and 82±31% in the sildenafil group; P=NS). However, in subjects who then received sildenafil, their second dobutamine response was significantly blunted, with peak power, ejection fraction, and end-systolic elastance changes reduced by 32±34%, 66±64%, and 56±63%, respectively (each P

KW - Contractility

KW - Pharmacology

KW - Phosphodiesterase 5

KW - Receptors, adrenergic, beta

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=27444439573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444439573&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.105.540500

DO - 10.1161/CIRCULATIONAHA.105.540500

M3 - Article

C2 - 16246964

AN - SCOPUS:27444439573

VL - 112

SP - 2642

EP - 2649

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 17

ER -